Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer

Nkarta Inc NKTX has collaborated with CRISPR Therapeutics AGCRSP to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program.
The companies will split all the R&D costs and any worldwide profits, 50/50.
CRISPR and Nkarta will start with a CAR-NK candidate targeting CD70 primarily for oncology indications. The target for their second CAR-NK program has yet to be revealed.
In addition to those programs, Nkarta can license CRISPR’s technology to edit five gene targets in an unlimited number of its own NK cell therapies.
For each non-collaboration candidate including a gene-editing target licensed from CRISPR, Nkarta will owe the company milestones and royalties on net sales.
The agreement includes a three-year exclusivity period between the companies.
Price Action: NKTX shares gained 8.96% at $20.18, while CRSP shares are up 2.62% at $110.67 on the last check Friday.